Head-to-head · WeighScore
Hims & Hers vs HumeCare+
By GLP-1 ScorecardUpdated
Score comparison
Hims & Hers has the higher recorded score — 75.6/100 to 58.6/100.
Hims & Hers grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mass-market app-first program with nationwide reach and consumer-grade polish.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Hims & Hers | HumeCare+ |
|---|---|---|
| WeighScore | 75.6/100 | 58.6/100 |
| Grade | C | C |
| Site position | #56 | #328 |
| Semaglutide | $199/mo | GLP-1 page advertises $199 billed monthly and a first four-week supply; homepage labels a three-month plan from $199/month. Confirm the selected total and formulation additions. |
| Tirzepatide | Not disclosed | Named on the public GLP-1 menu, but no separate current public prescription price confirmed; obtain the selected medication and renewal quote. |
| Coverage | All 50 states | Homepage/footer exclude Louisiana and Mississippi; GLP-1 FAQ also excludes Alabama. Confirm current treatment-specific eligibility, especially Alabama. |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #56 · C
FDAWarning letter issued to Hims & Hers Health, Inc. dba Hims in September 2025. See the FDA warning-letter database.
Strengths
- Nationwide
- Polished app
- Strong brand trust
What to consider
- Tirzepatide pricing inconsistently disclosed
- Industry-wide compounding scrutiny
Site position #328 · C
Strengths
- Advertises a Hume Pod and app within the homepage package; other selected plans may differ
- Current terms describe a single subscription including consultation and prescribed fulfilled medication, with added charges requiring disclosure and consent
- Publicly identifies MDI Medical Group PC as the clinical network and provides a clinician directory; assignment and current individual licenses still need confirmation
- Terms allow cancellation before renewal through the account Subscription section or support email
What to consider
- Homepage three-month pricing and the GLP-1 page’s monthly billing description do not establish one selected initial charge or renewal calendar
- Ninety-day, 180-day and six-month results-refund advertisements do not have matching claim rules in the current terms; customer-canceled prepaid periods are not prorated
- Muscle-preservation, side-effect and outcome advantages are merchant claims, not established benefits of the prescribed compound or tracking device
- No exact prescribing dose, vial quantity, usable supply or patient-lab price is confirmed by the public package
- The dispensing pharmacy and physical compounder are not named in the reviewed terms or shipping policy
- Alabama availability differs between the GLP-1 FAQ and site footer; general eligibility does not guarantee every preparation
- Next-day advertising differs from published clinical-review, pharmacy-processing and carrier estimates; a free included device does not create a separate device cash refund
Featured provider
HumeCare+
HumeCare+ scores 58.6/100 (C). Pairs advertised GLP-1 care with connected body-composition tracking, while public pages differ on payment periods, delivery and refund promises.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.